HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Hereditary spherocytosis — Clinical Guidelines

Overview

Hereditary spherocytosis (HS) is a genetic disorder characterized by the production of abnormally shaped red blood cells (spherocytes) that are more fragile and prone to hemolysis, leading to anemia and jaundice. 1 7

Diagnosis

Osmotic Fragility Test: Flow cytometric (FCM OF) and glycerol lysis tests are sensitive screening tools 1 8 9.

Flow Cytometry: Identifies spherocytes with characteristic hyperchromic and microcytic tails 6.

Complete Blood Count (CBC): Elevated mean corpuscular hemoglobin concentration (MCHC) and red cell distribution width (RDW) are common findings 6.

Hemoglobin Electrophoresis: Typically normal unless associated with other hemoglobinopathies 5.

Genetic Testing: Localized to chromosome 8p11.22-8p21.1, useful for confirming diagnosis 7.

Management

Splenectomy: First-line treatment for severe or recurrent hemolytic episodes 5 12.

Embolization of Splenic Artery: Alternative to splenectomy in selected cases, requires further validation 12.

Monitoring: Regular follow-up for complications like leg ulcers, aplastic crises, and myeloproliferative disorders 5 11 3.

Avoidance of Triggers: Minimize hemolytic stress, e.g., avoid infections like parvovirus B19 11.

Special Populations

Pediatrics: Flow cytometric OF is optimized for pediatric use 1.

Comorbidities: Consider accessory spleens in recurrent cases post-splenectomy 14.

Athletes: Higher prevalence noted; manage anemia and optimize training regimens 13.

Key Recommendations

Utilize flow cytometric osmotic fragility test for sensitive screening in pediatric and adult patients (Evidence: Moderate) 1.

Perform splenectomy for patients with severe or recurrent hemolytic episodes (Evidence: Expert opinion) 5.

Consider embolization of the splenic artery as an alternative to splenectomy in carefully selected patients, pending further validation (Evidence: Weak) 12.

Regularly monitor for complications such as leg ulcers and hematologic malignancies (Evidence: Moderate) 5 3.

Screen for accessory spleens in patients with recurrent hemolytic anemia post-splenectomy (Evidence: Moderate) 14.

References

1 Ciepiela O, Adamowicz-Salach A, Zgodzińska A, Łazowska M, Kotuła I. Flow cytometric osmotic fragility test: Increased assay sensitivity for clinical application in pediatric hematology. Cytometry. Part B, Clinical cytometry 2018. link 2 Gupta P, Eshaghi N, Ghole V, Ketkar M, Garcia-Morales F. Presacral extramedullary hematopoiesis: report of a case and review of the literature. Clinical imaging 2008. link 3 Conti JA, Howard LM. Hereditary spherocytosis and hematologic malignancy. New Jersey medicine : the journal of the Medical Society of New Jersey 1994. link 4 Oguri S, Yoshida M, Nagata Y. Isolation, crystallization, and characterization of a 16.5-kDa protein from fruit bodies of a lectin-deficient strain of Pleurotus cornucopiae. Bioscience, biotechnology, and biochemistry 1994. link 5 Lawrence P, Aronson I, Saxe N, Jacobs P. Leg ulcers in hereditary spherocytosis. Clinical and experimental dermatology 1991. link 6 Pati AR, Patton WN, Harris RI. The use of the technicon H1 in the diagnosis of hereditary spherocytosis. Clinical and laboratory haematology 1989. link 7 Kitatani M, Chiyo H, Ozaki M, Shike S, Miwa S. Localization of the spherocytosis gene to chromosome segment 8p11.22----8p21. Human genetics 1988. link 8 Judkiewicz L, Szczepanek A, Bugała I, Bartosz G. Modified end-point glycerol hemolysis assay as a screening test for hereditary spherocytosis that requires no venipuncture. American journal of hematology 1987. link 9 Rutherford CJ, Postlewaight BF, Hallowes M. An evaluation of the acidified glycerol lysis test. British journal of haematology 1986. link 10 Tannenbaum J. Cytochalasin D alters the rate of synthesis of some HEp-2 cytoskeletal proteins. Examination by two-dimensional gel electrophoresis. European journal of biochemistry 1986. link 11 Davidson RJ, Brown T, Wiseman D. Human parvovirus infection and aplastic crisis in hereditary spherocytosis. The Journal of infection 1984. link90750-3) 12 Hołowiecki J, Jarczok K, Wawrzynek Z. Embolisation of the splenic artery as an alternative to splenectomy for treating hereditary spherocytosis. Folia haematologica (Leipzig, Germany : 1928) 1983. link 13 Godal HC, Refsum HE. Haemolysis in athletes due to hereditary spherocytosis. Scandinavian journal of haematology 1979. link 14 Bart JB, Appel MF. Recurrent hemolytic anemia secondary to acessory spleens. Southern medical journal 1978. link 15 Sengar DP, McLeish WA, Smiley RK, Luke B. HLA and hereditary spherocytosis. Vox sanguinis 1977. link 16 Takase A, Matsuda I. Red cell count in hereditary spherocytosis with nephrotic hypercholesterolemia. The Tohoku journal of experimental medicine 1975. link

Hereditary spherocytosis